Validating Gulf War Illness Blood Biomarkers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorRoskamp Institute Inc.
About this trial
The investigators goals are to identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.
Eligibility criteria
Qualifiers
Age 35 years or older.
For GWI cases, served in the 1990-1991 Gulf War as active duty, national guard, or reserves and meet criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
For controls, must be a veteran in the same age range as those veterans with GWI as defined above.
Ability to understand written and spoken English or availability of a legal representative who can understand written or spoken English. Participants and caregiver/informants must be able to read, write and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate testing.
Disqualifiers
Cancer (except for non-melanoma skin cancers)
Chronic infectious disease
Problems resulting from postwar injuries.
Liver disease
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 2 trial groupsSponsors and collaborators
Roskamp Institute Inc.
Lead sponsor
Boston University
Collaborator
Palo Alto Veterans Institute for Research
Collaborator
United States Department of Defense
Collaborator
Source ClinicalTrials.gov